M Scott Maguire
Chief Executive Officer
M Scott Maguire joined Xenetic in April 2004 as Chief Executive Officer. He has more than 22 years of life sciences and healthcare investment banking executive experience and he has advised many U.S. and European companies on capital raisings, M&A and commercial development. Mr. Maguire began his banking career with Merrill Lynch based in New York. He later joined the healthcare division of W.R. Grace National Medical Care based in Waltham, MA, where he helped expand the international healthcare division and doubled international revenues through mergers and acquisitions. In 1996, he moved to Europe to co-found the Arthur Andersen global healthcare corporate finance practice based in London. Mr. Maguire is currently non-executive director of Healthcare Capital Partners Limited, a healthcare corporate finance and investment boutique he co-founded in 2002, and a non-executive director of Renal Services Ltd, a company focused on dialysis service provision in the UK. Mr. Maguire earned his M.B.A.
Roger Kornberg, Ph.D.
Nobel Prize Laureate in Chemistry - Studies of the Molecular Basis of Eukaryotic Transcription
Dr. Kornberg was appointed to the Board of Directors of the Company in February 2016. Dr. Kornberg is a member of the U.S. National Academy of Sciences and the Winzer Professor of Medicine in the Department of Structural Biology at Stanford University. He earned his bachelor's degree in chemistry from Harvard University in 1967 and his Ph.D. in chemical physics from Stanford in 1972. He became a postdoctoral fellow at the Laboratory of Molecular Biology in Cambridge, England and then an assistant professor of biological chemistry at Harvard Medical School in 1976, before moving to his present position as professor of structural biology at Stanford Medical School in 1978. In 2006, Dr. Kornberg was awarded the Nobel Prize in Chemistry in recognition for his studies of the molecular basis of Eukaryotic Transcription, the process by which DNA is copied to RNA. Dr. Kornberg is also the recipient of several awards, including the 2001 Welch Prize, the highest award granted in the field of chemistry in the United States, and the 2002 Leopald Mayer Prize, the highest award granted in the field of biomedical sciences from the French Academy of Sciences.
Firdaus Jal Dastoor, FCS
Firdaus Dastoor was appointed non-executive Director of Xenetic in July 2007. Mr. Dastoor is a Fellow Member of The Institute of Company Secretaries of India. He began his career as the Company Secretary of the Poonawalla Group. He then took on assignments involved in business development strategies and operations. He is on the board of several companies in the fields of engineering products, life sciences and biotech, international trade, financial services and quality standards certifications. Currently, Mr. Dastoor is a Group Director of the Poonawalla Group of Companies and in charge of Finance and Corporate Affairs.
Darlene Deptula-Hicks was appointed to the Board of Directors in April 2014. Ms. Deptula-Hicks is an accomplished financial executive in the life sciences and medical technology industries, with nearly 30 years' experience leading financial operations for both public and private global companies. Ms. Deptula-Hicks is currently the Senior Vice President and Chief Financial Officer of T2 Biosystems, Inc., an emerging leader in the field of in vitro diagnostics. Prior to T2, she served as Senior Vice President and Chief Financial Officer at Pieris Pharmaceuticals, Inc., a publicly traded clinical stage biotechnology company developing therapeutics to treat challenging immunology-related diseases; Executive Vice President and Chief Financial Officer of Microline Surgical, Inc., a global surgical instruments and medical devices company; and Executive Vice President and Chief Financial Officer of iCAD, Inc., a publicly traded medical device company. Ms. Deptula-Hicks has also served as Chief Financial Officer for a variety of other biotechnology and medical device companies. Ms. Deptula-Hicks completed an executive education program at Dartmouth College's Tuck School of Business, received her MBA from Rivier College, her bachelor's degree in accounting from Southern NH University. She also serves or has served on several public and private company boards since 2006.
Roman Knyazev was appointed to the Board of Directors in May 2014. Mr. Knyazev is an experienced financial professional and senior investment director at Rusano. Earlier, he worked at PriceWaterhouseCoopers Moscow and at Deloitte. Mr. Knyazev is a member of the SynBio Board of Directors and a Deputy Chairman at PharmSyntez, PETAR and Nanolek.
Jeffrey F. Eisenberg
Chief Operating Officer
Jeffrey F. Eisenberg joined the Xenetic Management team in December 2016 and has served on the Company’s Board of Directors since July 2016. He is a life sciences executive with over 20 years of operational experience and a successful track record in value creation in both private and public companies. Over the course of his career, he has led all crucial areas of R&D, operations, manufacturing/quality, business development, strategic partnering, product development, commercialization, and talent management. Prior to joining the Xenetic Board, Mr. Eisenberg served at Noven Pharmaceuticals, Inc. for over a decade beginning as Vice President, General Counsel and Corporate Secretary and departing as the President and CEO and a member of the Board of Directors. Mr. Eisenberg also served as Senior Vice President of Strategic Alliances, Interim President and CEO, and Executive Vice President while serving at Noven. Currently, Mr. Eisenberg serves as a member of the Board of Directors of Mabvax Therapeutics, Inc.
Edward J. Benz, Jr., M.D.
Dr. Benz is a renowned expert in blood disorders and is board certified in both hematology and internal medicine. He is an active clinical hematologist and a National Institutes of Health (NIH) funded researcher with a focus on the molecular basis and genetics around inherited blood disorders. Prior to joining the Xenetic Board, Dr. Benz served as President and CEO Emeritus of Dana-Farber Cancer Institute and the Richard and Susan Smith Professor of Medicine and Professor of Genetics at Harvard Medical School. During Dr. Benz’s tenure at Dana-Farber, the institute experienced exponential growth, including an increase of fund-raising to more than $200 million a year from a network of 300,000 donors, a tripling of the number of patients seeking treatment, and a growth in revenues from $265 million to more than $1 billion.
Prior to his role at Dana-Farber, Dr. Benz served as the chairman for the Department of Medicine and Sir William Osler Professor of Medicine at Johns Hopkins University School of Medicine, as well as physician-in-chief at Johns Hopkins Hospital. Dr. Benz has also served as President of the American Society of Hematology, the Association of American Cancer Institutes, the American Society for Clinical Investigation, the American Clinical and Climatological Society, and the Friends of the National Institute of Nursing Research. Over the course of his career, Dr. Benz has authored more than 300 articles, books, reviews and abstracts and has received numerous awards including the Margaret L. Kripke Legend Award, the American Society of Hematology Mentoring Award in Basic Science, and Leon Resnick Awards for Research.
Dr. Benz earned his bachelor’s degree from Princeton University. He received his Doctor of Medicine from Harvard Medical School, completed his medical school thesis at Boston Children’s Hospital and completed his training at the National Institutes of Health, Yale University School of Medicine and Brigham and Women’s Hospital in Boston, MA.